Navigating SG&A Expenses: A Tale of Two Biotechs

In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and TG Therapeutics, Inc. over the past decade, offering insights into their financial strategies.

Exelixis, Inc.: A Steady Climb

From 2014 to 2023, Exelixis, Inc. has seen a remarkable increase in SG&A expenses, growing by over 900%. This upward trend reflects the company's strategic investments in marketing and administrative capabilities, crucial for supporting its expanding portfolio.

TG Therapeutics, Inc.: A Volatile Journey

Conversely, TG Therapeutics, Inc. experienced a more volatile trajectory. Despite a significant spike in 2020, their SG&A expenses have fluctuated, indicating a more reactive approach to market dynamics.

Understanding these trends provides valuable insights into how these companies navigate the competitive biotech landscape.